NPI: 1023077328 · BALTIMORE, MD 21218 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 03/23/2006
Authorized official WINSTEL, JOHN controls 20+ related entities in our dataset. Read more
| Authorized Official | WINSTEL, JOHN (CHIEF ACCOUNTING OFFICER) |
| NPI Enumeration Date | 03/23/2006 |
Other providers sharing the same authorized official: WINSTEL, JOHN
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 16,470 | $75K |
| 2019 | 13,696 | $94K |
| 2020 | 8,801 | $126K |
| 2021 | 5,926 | $99K |
| 2022 | 2,784 | $67K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 90999 | Unlisted dialysis procedure, inpatient or outpatient | 6,557 | 957 | $305K |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 20,775 | 1,165 | $128K |
| J1756 | Injection, iron sucrose, 1 mg | 2,903 | 782 | $16K |
| J1270 | Injection, doxercalciferol, 1 mcg | 10,461 | 983 | $6K |
| A4657 | Syringe, with or without needle, each | 3,428 | 1,229 | $4K |
| 83970 | 635 | 590 | $1K | |
| 85041 | 967 | 833 | $0.00 | |
| 83540 | 319 | 285 | $0.00 | |
| 85048 | 910 | 791 | $0.00 | |
| 83550 | 319 | 284 | $0.00 | |
| 82728 | 314 | 285 | $0.00 | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 89 | 45 | $0.00 |